Boston Scientific Corporation $BSX Shares Acquired by SMART Wealth LLC

SMART Wealth LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 132.1% in the 3rd quarter, Holdings Channel reports. The firm owned 18,092 shares of the medical equipment provider’s stock after buying an additional 10,296 shares during the quarter. SMART Wealth LLC’s holdings in Boston Scientific were worth $1,766,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Steph & Co. acquired a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp raised its stake in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the third quarter worth $25,000. Finally, United Community Bank boosted its stake in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $74.72 on Monday. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $110.76 billion, a price-to-earnings ratio of 38.51, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $72.69 and a twelve month high of $109.50. The business has a 50 day simple moving average of $90.93 and a 200-day simple moving average of $97.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The firm’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent analyst reports. Oppenheimer cut their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. Canaccord Genuity Group dropped their target price on Boston Scientific from $131.00 to $112.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Citigroup reduced their price target on Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Mizuho dropped their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, TD Cowen decreased their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $109.43.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.